Overview

An Open Label Prostate Cancer Study in Japanese Patients

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The primary aim of study is to gain an initial assessment of safety and tolerability of AZD3514 in Japanese patients together with assessing Pharmacokinetics (PK) and gaining a preliminary assessment of anti-tumour action. In this study, AZD3514 will be administered to Japanese patients with metastatic castration resistant prostate cancer.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca